These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16673801)

  • 1. Alefacept in the treatment of psoriatic nail disease: a proof of concept study.
    Parrish CA; Sobera JO; Robbins CM; Cantrell WC; Desmond RA; Elewski BE
    J Drugs Dermatol; 2006 Apr; 5(4):339-40. PubMed ID: 16673801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
    Scheinfeld N
    J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alefacept in the treatment of psoriatic nail disease: a small case series.
    Cassetty CT; Alexis AF; Shupack JL; Strober BE
    J Am Acad Dermatol; 2005 Jun; 52(6):1101-2. PubMed ID: 15928640
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of severe nail psoriasis with etanercept.
    Coelho JD; Diamantino F; Lestre S; Ferreira AM
    Indian J Dermatol Venereol Leprol; 2011; 77(1):72-4. PubMed ID: 21220889
    [No Abstract]   [Full Text] [Related]  

  • 5. Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be?
    Körver JE; van de Kerkhof PC; Pasch MC
    J Am Acad Dermatol; 2006 Apr; 54(4):742-3. PubMed ID: 16546613
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic effects of a 12-week course of alefacept on nail psoriasis.
    Körver JE; Langewouters AM; Van De Kerkhof PC; Pasch MC
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1252-5. PubMed ID: 17062041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
    Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of psoriatic nails with indigo naturalis oil extract: a non-controlled pilot study.
    Lin YK; See LC; Chang YC; Huang YH; Chen JL; Tsou TC; Leu YL; Shen YM
    Dermatology; 2011; 223(3):239-43. PubMed ID: 22056841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
    Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
    Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alefacept for psoriasis and psoriatic arthritis.
    Gottlieb AB
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv58-60. PubMed ID: 16239390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
    Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
    J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study.
    De Simone C; Maiorino A; Tassone F; D'Agostino M; Caldarola G
    J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):1003-6. PubMed ID: 22788697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of nail psoriasis with adalimumab: an open label unblinded study.
    Rigopoulos D; Gregoriou S; Lazaridou E; Belyayeva E; Apalla Z; Makris M; Katsambas A; Ioannides D
    J Eur Acad Dermatol Venereol; 2010 May; 24(5):530-4. PubMed ID: 19807825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
    Ortonne JP; Khemis A; Koo JY; Choi J
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriatic nail disease: quality of life and treatment.
    Gupta AK; Cooper EA
    J Cutan Med Surg; 2009; 13 Suppl 2():S102-6. PubMed ID: 19799826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series.
    Shah A; O'Neill J; Feldman SR
    J Drugs Dermatol; 2010 Dec; 9(12):1491-4. PubMed ID: 21120256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
    Ortonne JP; Prinz JC
    Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of biological agents in the treatment of nail psoriasis.
    Zaiac M
    Am J Clin Dermatol; 2010; 11 Suppl 1():27-30. PubMed ID: 20586503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic agents in nail psoriasis: efficacy data and considerations.
    Kyriakou A; Patsatsi A; Sotiriadis D
    Expert Opin Biol Ther; 2013 Dec; 13(12):1707-14. PubMed ID: 24156504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
    Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
    J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.